A Phase 2 interventional study of Ipilimumab in Melanoma and Brain Metastases, sponsored by Grupo Español Multidisciplinar de Melanoma. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Grupo Español Multidisciplinar de Melanoma · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.
Among the 155 studies testing ipilimumab in Melanoma, this one is the 59th largest by enrollment of the 152 interventional ones that give a count, is one of 11 that started in 2014, is one of 83 in phase 2, and was the 72nd registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ipilimumab is the treatment under test here. Read study by study →
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 103 · Phase 3 14 · Phase 4 2
First in 2001; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 30 across the 152 interventional studies. Of the 102 that completed or were terminated, 56 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 155 have an industry lead sponsor. The 10 most frequent:
Grupo Español Multidisciplinar de Melanoma is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma: 2 open now, 4 under way, none of them phase 3. Of 7 finished, 3 (43%) have results posted.
Among the 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma, this one is the only one that started in 2014, is one of 8 in phase 2, and was the 2nd registered.
Grupo Español Multidisciplinar de Melanoma’s Melanoma studies by the year they started, since 2013.
8 of the studies testing ipilimumab in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT05289193Memorial Sloan Kettering Cancer CenterCD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | 2027-03-11 |
| NCT07422779Institute of Oncology LjubljanaImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | 2027-03-31 |
| NCT03122522Memorial Sloan Kettering Cancer CenterA Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 155 studies testing ipilimumab in Melanoma, from their registry updates:
Among Grupo Español Multidisciplinar de Melanoma’s 11 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ipilimumab adds a clinical benefit to radiation therapy in patients with melanoma metastatic to the brain.
Melanoma is the third most common cancer causing brain metastases, after cancers of the lung and breast, which appears to reflect the relative propensity of melanoma to metastasize to the central nervous system (CNS). Brain metastases are responsible for 20 to 54 percent of deaths in patients with melanoma, and among those with documented brain metastases, these lesions contribute to death in up to 95 percent of cases, with an estimated median overall survival ranging between 1.8 and 10.5 months, depending upon other prognostic factors.
Ipilimumab is an anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) monoclonal antibody that has demonstrated a clinically relevant and statistically significant improvement in overall survival, either alone (second line) or in combination with dacarbazine (DTIC) in 1st line.
Ipilimumab has shown activity against brain metastases.
According to the European Medicines Agency (EMA) approved label for Yervoy®, the use of glucocorticoids at baseline (commonly prescribed when brain metastases are diagnosed) should be avoided before the administration of ipilimumab. Data show that the use of even high doses of glucocorticoids for the management of immune-related adverse events do not decrease the efficacy of Yervoy®. There is no documented experience on the efficacy of Yervoy® when given concomitantly with radiation therapy and glucocorticoids.
In experimental models, radiation therapy is synergistic to anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) strategies (abscopal effect).
There are no published results from clinical trials on the interaction between radiation therapy and ipilimumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function as determine by the following criteria:
Exclusion Criteria:
Patients with melanoma and with any of the following disease-specific characteristics:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
Drug: Ipilimumab
Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
Also known as: Experimental
1-year Survival Rate
During treatment period, there will be assessments every cycle. After end of treatment every 3 month.
Time frame: From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months. Up to 1 year
Progression-Free Survival (PFS)
Median time from treatment initiation to progression of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Intracranial PFS
median, 6-month PFS rate
Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Extracranial PFS
median, 6-month PFS rate
Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Overall Survival
median value for OS estimated by kaplan meier method
Time frame: From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months.
Response Rate
Measured according to Who response criteria and Immune-related response criteria. Response for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Adverse Event Rates
Number of patients with at least one treatment-related toxicity, classified by grade.
Time frame: From date of inclusion until the date of first documented date of death from any cause or end of study, assessed every 3 weeks during for the first 6 months, then every 3 months.
Rate of Dose Delays/Reductions and Treatment Exposure.
Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)
Time frame: Expected average of 3 weeks during for the first 6 months, then every 3 months.
Correlation of Biomarker Expression and PFS.
Translational study. PFS outcome reported by subgroups according to BRAF mutation status
Time frame: Within 28 days before start treatment, just before the start treatment, then expected average of 3 weeks for the first 12 weeks
Intrapatient Variation of Quantitative Apparent Diffusion Coefficients of Serial Diffusion-weighted Magnetic Resonance Imaging
Time frame: Baseline and 4 weeks after WBRT
58 patients were enrolled and fulfilled the inclusion criteria, analyzed for safety. During the trial 7 patients discontinued treatment before completion, so the total of patients for efficacy analysis was 51.
| Milestone | Ipilimumab |
|---|---|
| Started | 58 |
| Completed | 51 |
| Not completed | 7 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Treatment discontinuation | 6 |
During treatment period, there will be assessments every cycle. After end of treatment every 3 month.
| Percentage of patients alive at 1 year | Ipilimumab |
|---|---|
| 1-year Survival Rate | 31.8 (18.8 to 44.8) |
Median time from treatment initiation to progression of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| Months | Ipilimumab |
|---|---|
| Progression-Free Survival (PFS) | 3.11 (2.23 to 3.98) |
median, 6-month PFS rate
No measurements were reported for this outcome.
median, 6-month PFS rate
No measurements were reported for this outcome.
median value for OS estimated by kaplan meier method
| Months | Ipilimumab |
|---|---|
| Overall Survival | 4.73 (3.59 to 5.87) |
Measured according to Who response criteria and Immune-related response criteria. Response for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Ipilimumab |
|---|---|
| modified WHO criteria — Complete Response (CR) | 2 |
| modified WHO criteria — Partial response (PR) | 3 |
| modified WHO criteria — Stable disease (SD) | 12 |
| modified WHO criteria — Progression disease (PD) | 19 |
| modified WHO criteria — Not evaluable (NE) | 15 |
| Immun related response criteria (irRC) — Complete Response (CR) | 2 |
| Immun related response criteria (irRC) — Partial response (PR) | 3 |
| Immun related response criteria (irRC) — Stable disease (SD) | 12 |
| Immun related response criteria (irRC) — Progression disease (PD) | 17 |
| Immun related response criteria (irRC) — Not evaluable (NE) | 17 |
Number of patients with at least one treatment-related toxicity, classified by grade.
| Participants | Ipilimumab |
|---|---|
| Any grade toxicity — Yes | 37 |
| Any grade toxicity — No | 21 |
| Grade 3 or higher toxicity — Yes | 11 |
| Grade 3 or higher toxicity — No | 47 |
Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)
| Participants | Ipilimumab |
|---|---|
| Ipilimumab delay — None | 43 |
| Ipilimumab delay — 1 event | 12 |
| Ipilimumab delay — 2 events | 2 |
| Ipilimumab delay — 3 events | 1 |
| Ipilimumab delay — 4 events | 0 |
| Ipilimumab reductions — None | 50 |
| Ipilimumab reductions — 1 event | 5 |
| Ipilimumab reductions — 2 events | 1 |
| Ipilimumab reductions — 3 events | 1 |
| Ipilimumab reductions — 4 events | 1 |
Translational study. PFS outcome reported by subgroups according to BRAF mutation status
| Participants | Ipilimumab |
|---|---|
| BRAF mutated — Progression disease | 5 |
| BRAF mutated — No progression | 12 |
| BRAF mutated — Not applicable | 34 |
| BRAF native — Progression disease | 7 |
| BRAF native — No progression | 19 |
| BRAF native — Not applicable | 25 |
Results for this outcome have not been posted.
Collected over Throughout the study period, from inclusion to 30 days after treatment has ended. Approximately 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ipilimumab | 40/58 (69%) | 33/58 (56.9%) | 57/58 (98.3%) |
| Event | Ipilimumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 6/58 |
| MalaiseGeneral disorders | 4/58 |
| HeadacheNervous system disorders | 3/58 |
| Cognitive disturbanceNervous system disorders | 2/58 |
| FeverGeneral disorders | 2/58 |
| Lung infectionInfections and infestations | 2/58 |
| SeizuresNervous system disorders | 2/58 |
| Thromboembolic eventVascular disorders | 2/58 |
| Urinary tract infectionInfections and infestations | 2/58 |
| VomitingGastrointestinal disorders | 2/58 |
| Event | Ipilimumab |
|---|---|
| FatigueGeneral disorders | 28/58 |
| HeadacheNervous system disorders | 23/58 |
| NauseaGastrointestinal disorders | 16/58 |
| AnorexiaMetabolism and nutrition disorders | 15/58 |
| DiarrhoeaGastrointestinal disorders | 14/58 |
| PruritusSkin and subcutaneous tissue disorders | 13/58 |
| AlopeciaSkin and subcutaneous tissue disorders | 9/58 |
| VomitingGastrointestinal disorders | 9/58 |
| DizzinessNervous system disorders | 7/58 |
| FeverGeneral disorders | 7/58 |
| Age, Continuous(Years) | Ipilimumab |
|---|---|
| Median | 66 (36.8 to 84.5) |
| Sex: Female, Male(Participants) | Ipilimumab |
|---|---|
| Female | 22 |
| Male | 36 |
| Region of Enrollment(Participants) | Ipilimumab |
|---|---|
| Spain | 58 |
| Karnofsky performance status (KPS)(Participants) | Ipilimumab |
|---|---|
| 90-100 | 42 |
| 70-80 | 15 |
| Not evaluable (NE) | 1 |
| Barthel index(Participants) | Ipilimumab |
|---|---|
| Lower than 15 | 2 |
| 15-20 | 56 |
| BRAF mutational status(Participants) | Ipilimumab |
|---|---|
| Mutated | 20 |
| Native | 30 |
| Not evaluated (NE) | 8 |
| Number of previous treatment lines(Participants) | Ipilimumab |
|---|---|
| No previous lines | 29 |
| 1 previous line | 20 |
| 2 or more previous lines | 9 |
| Number of brain metastasis(Participants) | Ipilimumab |
|---|---|
| Single brain lesion | 14 |
| Multiple brain lesions | 43 |
| Not especified (NE) | 1 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in Dec 2016, 32 months.
Results were first posted in Jul 2021, 4 years 6 months after primary completion.
Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 32 months is below that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ipilimumab
Grupo Español Multidisciplinar de Melanoma